Congress targets pill-press diversion to combat fentanyl manufacturing
S. 2870 — Fight Illicit Pill Presses Act · Filed by John Cornyn (R-TX) · 15 cosponsors · Introduced Sep 18, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill amends the Controlled Substances Act to require manufacturers, distributors, and sellers of tableting and encapsulating machines—equipment used to produce pills and capsules—to permanently affix serial numbers to these machines and their critical parts (punches and dies). The bill also requires regulated persons to report these serial numbers to the Attorney General and makes it illegal to remove, alter, or obliterate the serial numbers. The goal is to track pill-press equipment and prevent its diversion to illegal drug manufacturing.
Why we flagged it
The bill's core mechanism is a regulatory tracking system for pill-press equipment, designed to disrupt the supply chain feeding illegal drug manufacturing. It is a straightforward law-enforcement tool with no hidden riders or private carve-outs.
What the text implies
- Manufacturers of legitimate pill-press equipment will incur compliance costs (serial-number affixing, record-keeping, reporting), which may be passed to pharmaceutical and supplement companies, potentially raising production costs for legal products.
- The bill requires the Attorney General to provide guidance on retrofitting machines manufactured before enactment, creating a retroactive compliance burden on existing equipment owners.
- Serial-number reporting to the Attorney General creates a federal database of pill-press ownership and distribution, which could be used for broader surveillance or regulatory purposes beyond drug enforcement.
Section numbers refer to the bill text the analysis read — linked under Primary records below.
Who it affects
The bill strengthens law-enforcement tools to combat the diversion of pill-press equipment to illegal drug manufacturing, particularly fentanyl production. Ordinary citizens benefit from reduced supply of illicit pills and lower overdose risk, with minimal direct burden on the public (the compliance cost falls on manufacturers and distributors, not consumers).
Named in the bill
Attorney General, Controlled Substances Act, DEA (implied enforcement agency), Manufacturers of tableting machines, Manufacturers of encapsulating machines, Pharmaceutical industry, Supplement industry
Where it stands
15 cosponsors: 7 Democrats, 7 Republicans, 1 Independents.
- Sep 18, 2025 — Introduced · Congress.gov: “Introduced in Senate”
- Sep 18, 2025 — Referred to Senate Committee on the Judiciary · Congress.gov: “Read twice and referred to the Committee on the Judiciary”
Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.
Money around this bill
1 lobbying clients named this bill on 1 disclosure filings across 1 quarter, Sep 2025 to Sep 2025. Those filings disclosed $40,000 in lobbying spend. A filing names 9 bills on average, so that figure is what each filing reported, not a share belonging to this bill.
More lobbying clients named this bill than 0% of bills with at least one filing.
John Cornyn, the sponsor, reported $1,976,234 in PAC receipts in the 2026 cycle.
- Sergeants Benevolent Association of New York City — $40,000 on 1 filing
Lobbying Disclosure Act filings through Oct 13, 2025. A filing shows who paid to lobby on a bill it names, not what changed.
How this was measured
Analysis — Quorum's AI read the bill text published by Congress.gov (4,836 characters) on Nov 7, 2026. Section numbers in the findings refer to that text, linked below; transparency and hidden-provision scores are compared against the median of 17,910 analysed bills.
Status and sponsors — Congress.gov's bill record — actions, committee referrals and cosponsors — loaded nightly. The timeline shows status changes, not every procedural action.
Money — Senate Lobbying Disclosure Act filings whose specific-issue field names this bill for quarters ending Sep 2025 to Sep 2025. A filing's amount is reported whole beside the median number of bills a filing names; it is never divided across them. PAC receipts are FEC-reported contributions to the sponsor's candidate committee in the 2026 cycle.
As of — lobbying records through Oct 13, 2025 · page rendered 2026-11-22.
“Congress targets pill-press diversion to combat fentanyl manufacturing” QuorumCivic. https://share.quorumcivic.app/bill/119/s2870 Report an error
The week in bills
One email, Sunday: what Congress passed, what it changed, and who paid.
One link arrives to confirm the address. It is used for this email and nothing else, and every issue carries an unsubscribe link.